Archives20242023202220212020201920182017201620152014201320122011 October 21, 2014ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France Read More October 21, 2014AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress Read More October 02, 2014INTERIM RESULTS ANNOUNCEMENT for the six months ended 30 June 2014 Read More October 02, 2014Lupuzor™ Gears Up To Start Pivotal Phase III trials Read More June 27, 2014ANNUAL GENERAL MEETING: 2014 Read More June 27, 2014ImmuPharma to access pioneering research in the Bordeaux region of France Read More June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More June 09, 2014PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More May 23, 2014Annual Report and Accounts Notice of Annual General Meeting: 27 June 2014 Read More May 06, 2014Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More April 23, 2014Dr. Slyviane Muller, founder of Lupuzor, presents at Osaka University, Japan Read More April 11, 2014ImmuPharma Sponsors the 2014 European Lupus Conference Read More 1…1819202122
October 21, 2014ImmuPharma awarded €400,000 grant in support of its pioneering research in the Bordeaux region of France Read More
October 21, 2014AVIVA lead investor in £3.4 million fund raising to support Lupuzor™ Pivotal Phase III Progress Read More
June 16, 2014New Nucant Patents. New Optically Pure Compounds for Improved Therapeutic Efficiency Read More
June 09, 2014PRELIMINARY RESULTS 2013: a year of substantial progress for the year ended 31 December 2013 Read More
May 06, 2014Dr. Sylviane Muller – Presentation Abstract from 2014 European Lupus Conference Read More
